Celltrion has taken a controlling stake in ADC specialist Iksuda as part of a $47m financing round that has just been closed by the UK-based company.
Celltrion says it has become the largest shareholder of UK-based antibody drug conjugates developer Iksuda by participating alongside Mirae Asset Capital and Premier Partners in a $47m financing round that has just closed.
The Korean firm said Iksuda’s efforts to develop “next-generation anti-cancer drugs,” along with its biotech and chemical R&D capabilities, would...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
